Our lab works towards better therapies for rare immune diseases

About us

Our focus

Our focus

Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.

Our aim

Our aim

We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.

Our methods

Our methods

We utilise custom genomics and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material.

Our team

Our team

Our international team is based at the Centre for Molecular Medicine Norway in Oslo, Norway.  We have diverse backgrounds and expertise in biosciences and clinical medicine.

Publications

Our research

Our main projects involve optimising genome editing, along with personalised use of targeted therapies in rare diseases. We’re interested in rare and undiagnosed immunological diseases.

Our research

Publications

See our latest studies and research highlights in genome editing and novel genetic etiologies of immunological diseases in chronological order.

Latest news

Who supports us?

NCMM logo

Centre for Molecular Medicine Norway

Visit site
Research Council of Norway logo

The Research Council of Norway

Visit site
Norwegian Cancer Society logo

Norwegian Cancer Society

Visit site
Helse Sør-Øst logo

South-Eastern Norway Regional Health Authority

Visit site
Oslo universitetssykehus logo

Oslo University Hospital

Visit site
Barncancer fonden logo

The Swedish Childhood Cancer Fund

Visit site
Academy of Finland logo

Academy of Finland

Visit site
Instrumentarium Science Foundation logo

Instrumentarium Science Foundation

Visit site